INDIANAPOLIS, September 19 — Eli Lilly and Company announced on Sept. 18, 2026, that the U.S. Food and Drug Administration granted full approval to Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy. The approval covers patients whose ESR1 mutation is detected by an FDA-authorized test. Inluriyo is an oral estrogen receptor antagonist; Verzenio is a CDK4/6 inhibitor.
Both are taken by mouth.
What the EMBER-3 trial showed
The decision rests on results from the Phase 3 EMBER-3 trial, which evaluated patients with metastatic breast cancer whose tumors harbor an ESR1 mutation. In the trial, patients received Inluriyo alone or Inluriyo in combination with Verzenio after an aromatase inhibitor, with or without a CDK4/6 inhibitor, in either the adjuvant or metastatic setting. According to the announcement, Inluriyo in combination with Verzenio doubled median progression-free survival compared to Inluriyo alone among patients with ESR1-mutated metastatic breast cancer.
The approval is based on the proven clinical benefit of switching to the combination at clinical progression. Lilly said the all-oral combination targets the two central drivers of ER-positive breast cancer, with an established tolerability profile and no new monitoring required.
Lilly’s oncology chief on the strategy
Jacob Van Naarden, executive vice president and president of Lilly Oncology, said in the announcement: “In less than a year since its approval, Inluriyo is the leading treatment option for people with ER+, HER2-, ESR1m metastatic breast cancer, now reaching over half of all patients starting an oral SERD.
Today’s full approval extends what Inluriyo in combination with Verzenio can do for patients, with a regimen that has confirmed benefit, is aligned to the clinically proven treatment paradigm of changing therapy at clinical progression, and doesn’t introduce burdensome monitoring requirements for patients or physicians.” Van Naarden added: “In fact, all available evidence suggests that switching endocrine therapy and CDK4/6 inhibitor at clinical progression improves patient outcomes more than switching therapy earlier.
Utilizing this evidence-based practice spares early exposure to additional side effects, reduces patient anxiety from unnecessary testing, and mitigates avoidable costs to the healthcare system.” The announcement states that the combination delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor.
What this means for patients
The approval was announced by Eli Lilly and Company on Sept. 18, 2026, with the news distributed via PR Newswire from Indianapolis. The FDA approval is for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, as detected by an FDA-authorized test. For patients already on endocrine therapy, the key point is that the ESR1 mutation must be identified through an FDA-authorized test before this combination becomes an option.
That testing step matters, and patients should discuss with their care team whether it applies to their situation. The encouraging part is that this is a full approval, not an accelerated one, and it comes with no new monitoring requirements — a meaningful consideration for anyone weighing the practical burden of a new regimen.
Early findings from EMBER-3 suggest the combination offers a real step forward for a group of patients who have limited options after their first line of treatment fails. What to watch next is how quickly testing for ESR1 mutations becomes routine in clinics, and whether real-world use mirrors the trial results. For now, the evidence supports a conversation between patients and their oncologists about whether this regimen fits their case. Consult your doctor for medical advice.
